Intrinsic tumour suppression

Nature

Volumn 432, Issue 7015, 2004, Pages 307-315

  Lowe, Scott W ^a   Cepero, Enrique ^a   Evan, Gerard ^b  

^a Simons Center for Quantitative Biology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGENS; CELLS; SENSORS;

CELL-CYCLE; MUTATIONS;

TUMORS;

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BIM PROTEIN; CASPASE; FAS ANTIBODY; PROTEIN BAX; PROTEIN P53;

MUTATION;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; GENE INDUCTION; GENE MUTATION; HISTOPATHOLOGY; MAMMAL CELL; MICROENVIRONMENT; MOLECULAR EVOLUTION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SENSOR; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MAMMALIA;

EID: 9244224723     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03098     Document Type: Review

References (99)

1. Evan, G. I. et al. Induction of apoptosisin fibroblasts by c-myc protein. Cell 69, 119-128 (1992).
2. Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348 (2001).
3. Fridman, J. S. & Lowe, S. W. Control of apoptosis by p53. Oncogene 22, 9030-9040 (2003).
4. Danial, N. N. & Korsmeyer, S. J. Cell death: critical control points. Cell 116, 205-219 (2004).
5. Gory, S., Huang, D. C. & Adams, J. M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22, 8590-8607 (2003).
6. Green, D. R. & Kroemer, G. The pathophysiology of mitochondrial cell death. Science 305, 626-629 (2004).
7. Peter, M. E. & Krammer, P. H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10, 26-35 (2003).
8. Wilkinson, J. C., Cepero, E., Boise, L. H. & Duckett, C. S. Upstream regulatory role for XIAP in receptor-mediated apoptosis. Mol. Cell. Biol. 24, 7003-7014 (2004).
9. Scaffidi, C. et al. Two CD95 (APO-1/Fas) signalling pathways. EMBO J. 17, 1675-1687 (1998).
10. Vogelstein, B., Lane, D, & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
11. Mihara, M. et al. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11, 577-590 (2003).
12. White, E. Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene 20, 7836-7846 (2001).
13. Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R. & Lowe, S. W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13, 2670-2677 (1999).
14. Symonds, H. et al. p53-dependent apoptosis suppresses tumour growth and progression in vivo. Cell 78, 703-711 (1994).
15. Pierce, A. M. et al. Increased E2F1 activity induces skin tumours in mice heterozygous and nullizygous for p53. Proc. Natl Acad. Sci. USA 95, 8858-8863 (1998).
16. Yin, C., Knudson, C. M., Korsmeyer, S. J. & Van Dyke, T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385, 637-640 (1997).
17. Hemann, M. T. et al. Suppression of tumorigenesis by the p53 target PUMA. Proc. Natl Acad. Sci. USA 101, 9333-9338 (2004).
18. Schmitt, C. A. et al. Dissecting p53 tumour suppressor functions in vivo. Cancer Cell 1, 289-298 (2002).
19. Pelengaris, S., Khan, M. & Evan, G. I. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109, 321-334 (2002).
20. Lowe, S. W. & Sherr, C. J. Tumour suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13, 77-83 (2003).
21. Sherr, C. J. The INK4a/ARF network in tumour suppression. Nature Rev. Mol. Cell Biol. 2, 731-737 (2001).
22. Zindy, F. et al. Myc signalling via the ARF tumour suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12, 2424-2433 (1998).
23. de Stanchina, E, et al. E1A signalling to p53 involves the p19(ARF) tumour suppressor. Genes Dev. 12, 2434-2442 (1998).
24. Kamijo, T. et al. Tumour suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659 (1997).
25. Schmitt, C. A. et al. A senescence programme controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346 (2002).
26. Jacobs, J. J. et al. Bmi-1 collaborates with c-Mycin tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 13, 2678-2690 (1999).
27. Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J. & Cleveland, J. L. Disruption of the ARF-Mdm2-p53 tumour suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13, 2658-2669 (1999).
28. Verschuren, E. W., Klefstrom, J., Evan, G. I. & Jones, N. The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell 2, 229-241 (2002).
29. Tolbert, D., Lu, X., Yin, C., Tantama, M. & Van Dyke, T. p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumour suppression in vivo. Mol. Cell. Biol. 22, 370-377 (2002).
30. Khan, S. H., Moritsugu, J. & Wahl, G. M. Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc. Natl Acad. Sci. USA 97, 3266-3271 (2000).
31. Rogoff, H. A. et al. Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Aun/Nbs1/Chk2. Mol. Cell. Biol. 24, 2968-2977 (2004).
32. Liao, M. J., Yin, C., Barlow, C., Wynshaw-Boris, A. & van Dyke, T. Atm is dispensable for p53 apoptosis and tumour suppression triggered by cell cycle dysfunction. Mol. Cell. Biol. 19, 3095-3102 (1999).
33. Conn, C. W., Lewellyn, A. L. & Mailer, J. L. The DNA damage checkpoint in embryonic cell cycles is dependent on the DNA-to-cytoplasmic ratio. Dev. Cell 7, 275-281 (2004).
34. Flores, E. R. et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560-564 (2002).
35. Urist, M. & Prives, C. p53 leans on its siblings. Cancer Cell 1, 311-313 (2002).
36. Yang, A., Kaghad, M., Caput, D. & McKeon, F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 18, 90-95 (2002).
37. Senoo, M., Manis, J. P., Alt, F. W. & McKeon, F. p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell 6, 85-89 (2004).
38. Irwin, M. S. et al. Chemosensitivity linked to p73 function. Cancer Cell 3, 403-410 (2003).
39. Bergarnaschi, D. et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3, 387-402 (2003).
40. Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T. & Prives, C. A subset of tumour-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21, 1874-1887 (2001).
41. Perez, D. & White, E. E1A sensitizes cells to tumour necrosis factor alpha by downregulating c-FLIP S. J. Virol. 77, 2651-2662 (2003).
42. Klefstrom, J., Verschuren, E. W. & Evan, G. c-Myc augments the apoptotic activity of cytosolic death receptor signalling proteins by engaging the mitochondrial apoptotic pathway. J. Biol. Chem. 277, 43224-43232 (2002).
43. Croxton, R., Ma, Y., Song, L., Haura, E. B. & Cress, W. D. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 21, 1359-1369 (2002).
44. Eischen, C. M. et al. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene 20, 6983-6993 (2001).
45. Egle, A., Harris, A. W., Bouillet, P. & Cory, S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl Acad. Sci. USA 101, 6164-6169 (2004).
46. Hershko, T. & Ginsberg, D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J. Biol. Chem. 279, 8627-8634 (2004).
47. Nahle, Z. et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nature Cell Biol. 4, 859-864 (2002).
48. Sears, R., Ohtani, K. & Nevins, J. R. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol. Cell. Biol. 17, 5227-5235 (1997).
49. Matsumura, I., Tanaka, H. & Kanakura, Y. E2F1 and c-Myc in cell growth and death. Cell Cycle 2, 333-338 (2003).
50. Leone, G. et al. Myc requires distinct E2F activities to induce S phase and apoptosis. Mol. Cell 8, 105-113 (2001).
51. Russell, J. L. et al. ARF differentially modulates apoptosis induced by E2F1 and Myc. Mol. Cell. Biol. 22, 1360-1368 (2002).
52. Baudino, T. A. et al. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol. Cell 11, 905-914 (2003).
53. Conner, E. A. et al. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene 19, 5054-5062 (2000).
54. Leone, G., DeGregori, J., Sears, R., Jakoi, L. & Nevins, J. R. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387, 422-426 (1997).
55. Dimri, G. P., Itahana, K., Acosta, M. & Campisi, J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumour suppressor. Mol. Cell. Biol. 20, 273-285 (2000).
56. Damalas, A., Kahan, S., Shtutman, M., Ben-Ze'ev, A. & Oren, M. Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J. 20, 4912-4922 (2001).
57. Serrano, M., Lin, A. W., McCurrach, M. E. Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-502 (1997).
58. Campisi, J. Cellular senescence as a tumour-suppressor mechanism. Trends Cell Biol. 11, 527-531 (2001).
59. Shay, J. W. & Roninson, I. B. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23, 2919-2933 (2004).
60. Pearson, M. et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406, 207-210 (2000).
61. Ferbeyre, G, et al. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14, 2015-2027 (2000).
62. Itahana, K. et al. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol. Cell. Biol. 23, 389-401 (2003).
63. Narita, M. et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703-716 (2003).
64. Paramio, J. M. et al. The ink4a/arf tumour suppressors cooperate with p21cip1/waf in the processes of mouse epidermal differentiation, senescence, and carcinogenesis. J. Biol. Chem. 276, 44203-44211 (2001).
65. Elenbaas, B. et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15, 50-65 (2001).
66. Horner, S. M., DeFilippis, R. A., Manuelidis, L. & DiMaio, D. Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. J. Virol. 78, 4063-4073 (2004).
67. Wu, X. & Levine, A. J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl Acad. Sci. USA 91, 3602-3606 (1994).
68. Benanti, J. A. & Galloway, D. A. Normal human fibroblasts are resistant to RAS-induced senescence. Mol. Cell. Biol. 24, 2842-2852 (2004).
69. Tuveson, D. A. et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-387 (2004).
70. Guerra, C. et al. Tumour induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111-120 (2003).
71. Lin, A. W. & Lowe, S. W. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc. Natl Acad. Sci. USA 98, 5025-5030 (2001).
72. Kelly-Spratt, K. S., Gurley, K. E., Yasui, Y. & Kemp, C. J. p19(Arf) suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol. 2, E242 (2004).
73. Pelengaris, S., Littlewood, T., Khan, M., Elia, G. & Evan, G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3, 565-577 (1999).
74. Raff, M. C. Social controls on cell survival and cell death. Nature 356, 397-400 (1992).
75. Askew, D., Ashmun, R., Simmons, B. & Cleveland, J. Constitutive c-myc expression in IL-3-dependent myeloid cell line suppresses cycle arrest and accelerates apoptosis. Oncogene 6, 1915-1922 (1991).
76. Harrington, E. A., Bennett, M. R., Fanidi, A. & Evan, G. I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 13, 3286-3295 (1994).
77. Grossmann, J. Molecular mechanisms of 'detachment-induced apoptosis-Anoikis'. Apoptosis 7, 247-260 (2002).
78. Vivano, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489-501 (2002).
79. Plas, D. R., Rathmell, J. C. & Thompson, C. B. Homeostatic control of lymphocyte survival: potential origins and implications. Nature Immunol. 3, 515-521 (2002).
80. Grad, J. M., Zeng, X. R. & Boise, L. H. Regulation of Bd-xL: a little bit of this and a little bit of STAT. Curr. Opin. Oncol. 12, 543-549 (2000).
81. LeRoith, D. & Helman, L. The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell 5, 201-202 (2004).
82. Christofori, G., Naik, P. & Hanahan, D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369, 414-418 (1994).
83. Orsulic, S. et al. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1, 53-62 (2002).
84. Kauffmann-Zeh, A. et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385, 544-548 (1997).
85. Wendel, H. G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332-337 (2004).
86. Zindy, F. et al. Arf tumour suppressor promoter monitors latent oncogenic signals in vivo. Proc. Natl Acad. Sci. USA 100, 15930-L5935 (2003).
87. Aslanian, A., Iaquinta, P. J., Verona, R. & Lees, J. A. Repression of the Arf tumour suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev. 18, 1413-1422 (2004).
88. Jin, S. et al. CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals. Genes Dev. 17, 359-367 (2003).
89. Zheng, T. S. et al. Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation. Nature Med. 6, 1241-1247 (2000).
90. Harlin, H., Reffey, S. B., Duckett, C. S., Lindsten, T. & Thompson, C. B. Characterization of XIAP-deficient mice. Mol. Cell. Biol. 21, 3604-3608 (2001).
91. Sage, J., Miller, A. L., Perez-Mancera, P. A., Wysocki, J. M. & Jacks, T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424, 223-228 (2003).
92. Seoane, J., Le, H. V. & Massague, J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729-734 (2002).
93. Johnstone, R. W., Ruefli, A. A. & Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164 (2002).
94. Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468-472 (1999).
95. Felsher, D. W. & Bishop, J. M. Reversible tumorigenesis by MYC in haematopoietic lineages. Mol. Cell 4, 199-207 (1999).
96. Gunther, E. J. et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 17, 488-501 (2003).
97. Moody, S. E. et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2, 451-461 (2002).
98. Pakunlu, R. I., Cook, T. J. & Minko, T. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defence by MDR1 and BCL-2 targeted antisense oligonudeotides enhances the anticancer efficacy of doxorubicin. Pharm. Res. 20, 351-359 (2003).
99. Bykov, V. J. & Wiman, K. G. Novel cancer therapy by reactivation of the p53 apoptosis pathway. Ann. Med. 35, 458-465 (2003).